Product
CD47 Antagonist ALX148
1 clinical trial
14 indications
Indication
Aggressive B-Cell Non-Hodgkin LymphomaIndication
Grade 2 Follicular LymphomaIndication
Marginal Zone LymphomaIndication
Follicular LymphomaIndication
LymphomaIndication
Indolent B-Cell Non-Hodgkin LymphomaIndication
Refractory High Grade B-Cell LymphomaIndication
Mantle Cell LymphomaIndication
Richter syndromeClinical trial
A Phase I/II Open Label, Single Center, Study of the Combination of ALX148, Rituximab and Lenalidomide in Patients With Indolent and Aggressive B-Cell Non-Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2026-03-10